Corteria Pharmaceuticals

Executive Summary

Corteria Pharmaceuticals is a privately held, Phase 2-stage biotech founded in 2021 and headquartered in Paris, France, focused on developing first-in-class small molecule therapies for high unmet need indications. Its primary area of focus is worsening and acute decompensated heart failure (ADHF), a condition with limited treatment options and high mortality. Additionally, the company is exploring its proprietary platform in sarcopenia and specific obesity subpopulations, leveraging innovative patient stratification strategies to identify responders. By targeting underlying mechanisms such as mitochondrial dysfunction and metabolic dysregulation, Corteria aims to provide transformative treatments that go beyond symptomatic relief. Despite being early-stage, the company's approach has the potential to address significant gaps in cardiovascular and metabolic disease management.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead heart failure candidate55% success
• Q1 2027Initiation of Phase 2b/3 trial in sarcopenia40% success
• TBDPartnership or licensing deal for obesity subpopulation program30% success